The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, ...

At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together ...

The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...

As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO.

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...